Exploring plant-based therapies for tuberculosis: A comprehensive review of natural alternatives for effective treatment

Corresponding author: Dr. K. Praveena. Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. Exploring plant-based therapies for tuberculosis: A comprehensive review of natural alternatives for effective treatment K. Praveena 1, *, S. Bharath 2, G. Boominathan 2, A. Dhinakaran 2, S. Gopinath 2, M. Gowtham Singh 2, E. Imayaa 2, S. Naveenkumar 2, V. Ponni 2 and S. Saraswathi 2 1 Department of Pharmacology, Smt. Gandhimathi College of Pharmacy, Tiruvannamalai. 2 Smt. Gandhimathi College of Pharmacy, Tiruvannamalai. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 Publication history: Received on 20 December 2024; revised on 02 February 2025; accepted on 05 February 2025 Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0118 Abstract Tuberculosis (TB), is caused by Mycobacterium tuberculosis, continues to challenge global health systems, compounded by the emergence of multidrug-resistant strains and the limitations of existing therapies. In response, plant-based approaches offer a promising alternative, leveraging bioactive compounds with anti-microbial, anti-inflammatory, and immunomodulatory properties. This review highlights the pharmacological potential of medicinal plants, including Curcuma longa, Azadirachta indica, and Acalypha indica, in combating TB. These plants exhibit mechanisms such as disrupting mycobacterium cell wall synthesis, enhancing host immunity, and reducing inflammation. By integrating plant-derived compounds with conventional therapies, the potential for more effective, sustainable, and accessible TB treatments emerges. Further research into these bioactive molecules and their mechanisms of action is essential for overcoming current therapeutic barriers and advancing global TB control. Keywords: Tuberculosis; Medicinal plants; Multidrug resistance-TB; Mycobacterium tuberculosis 1. Introduction :( 1-8) Tuberculosis (TB) is an airborne infectious disease caused by the bacteria Mycobacterium tuberculosis (Mtb), which is part of the Mycobacterium tuberculosis complex (MTBC) that includes other mycobacterium such as M. bovis, M. africanum, M. canettii, and M. microti. It is transmitted when a person with infectious TB expels droplet nuclei (airborne particles about 1-5 microns) through actions like coughing, sneezing, shouting, or singing, and these droplets are inhaled, reaching the alveoli of the lungs via the nasal passages, respiratory tract, and bronchi. Globally, TB has infected an estimated 2 billion people (about one-third of the world’s population), with 8.7 million new cases and 1.4 million deaths reported in 2011, of which 13% were co-infected with HIV. The disease primarily affects the lungs (pulmonary TB) but can also spread through the blood to other organs like the kidneys, spine, or brain (extra pulmonary TB). Pulmonary TB is infectious, whereas extra pulmonary TB is not. While TB is preventable and treatable, it remains one of the deadliest infectious diseases. After a decline in cases during 2020, TB cases have been increasing since 2021, with 2023reporting the highest numbers since 2013, including 9,633 cases in the United States 15.6% increase from 2022. Enhanced strategies to diagnose and treat latent TB and active TB are crucial to reversing this trend and achieving the goal of TB elimination. Although the primary mode of transmission is person-to-person through airborne particles, TB can occasionally spread to humans from infected cows via unsterilized milk, though this plays a minor role in the disease's overall epidemiology. Although it was anticipated that tuberculosis (TB) would be increasingly brought under control in many countries as the year 2000 approached, the last decade of the 20th century witnessed a global resurgence of the disease. In 1997, World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 115 the World Health Organization (WHO) estimated 7.96 million TB cases worldwide, with half being highly infectious, and over 1.9 million deaths, making TB the fifth leading cause of death from a single infectious agent. By 1998, approximately1.9 billion individuals one-third of the global population were infected with the tubercle bacillus, with more than 95% of cases occurring in Africa, Asia, and Latin America. However, TB cases increased in nearly every country, leading to its declaration as a "global emergency." The re-emergence of TB was attributed to several factors, including rising poverty, not only in developing nations but also among marginalized groups in industrialized countries; demographic growth, with a high number of children born in TB-endemic regions reaching age groups where the disease is more prevalent; the AIDS epidemic, which escalated TB cases in regions heavily affected by HIV; negligence by health authorities in prioritizing TB control; and the lack of effective National Tuberculosis Programmers (NTPs) or reliance on outdated strategies that led to chaotic treatment and multidrug-resistant TB. WHO projected that by 2000,TB cases would surpass 8.4 million, causing over 2 million deaths annually, and without significant improvements in TB control, the following decade could see 80 million new cases and nearly 20 million deaths, predominantly among individuals aged 20-49 years, the most economically active population group. Nonetheless, model TB control programmers, supported by WHO and the International Union Against Tuberculosis. 2. Etiology of Tuberculosis (TB) Tuberculosis (TB) is a contagious complaint primarily caused by Mycobacterium tuberculosis. It generally affects the lungs, though it can involve any organ in the body. The bacterium is transmitted from person to person through airborne patches when an individual with pulmonary TB coughs, sneezes, or speaks. This airborne transmission allows the bacteria to reach the lungs of a susceptible existent, where they may be getting infection. The development of active TB depends on several factors, including the vulnerable status of the existent. When an individual inhales the bacteria, the body’s vulnerable system responds by trying to contain the infection. In healthy individualities, the vulnerable system can frequently limit the spread of the bacteria, leading to a TB infection (LTBI). Still, in people with weakened vulnerable systems, similar as those with HIV/AIDS, malnutrition, or those witnessing immunosuppressive treatments, the bacteria can multiply, leading to active TB complaint. Threat factors for TB also include dragged close contact with an infected person, living or working in crowded conditions, and being in regions with high TB frequency. Also, inheritable factors may play a part in vulnerability to TB, as some individualities may have inherited vulnerable system characteristics that make them more prone to developing active TB after exposure. In addition to M. tuberculosis, other mycobacterium species can begetting TB such like conditions, including Mycobacterium Bovis, which primarily affects creatures but can also infect humans, generally through the consumption of unpasteurized milk or direct contact with infected creatures. The pathogenesis of TB involves the original entry of M. tuberculosis into the lungs, where it's phagocytosed by macrophages. The bacterium is suitable to survive and replicate within these vulnerable cells, ultimately leading to granuloma conformation. This granuloma represents a controlled vulnerable response aimed at containing the infection. Still, if the granuloma fails to contain the bacteria, or if the vulnerable system is compromised, the bacteria can spread, leading to active complaint. Lung Disease in countries like Benin, China, Guinea, Nicaragua, Peru, and Tanzania, demonstrated effective strategies for combating the complaint. 3. Pathophysiology Tuberculosis infections begin with the inhalation of M. tuberculosis bacilli into the airways, where they spread to the lungs, lymph bumps, and distant spots via the bloodstream. During haematogenous dispersion, mycobacterium can deposit near the ventricles or subarachnoid space, leading to granuloma conformation. Postmortem examination studies show this granuloma in the CNS, indeed in those without suspected CNS involvement. Rich and McCordock proposed that rupture of this granuloma, known as a “Rich focus,” triggers the seditious response and initiates tuberculosis meningitis. Recent exploration suggests that variations in host impunity and M. tuberculosis strains may impact this process. CNS infections by M. tuberculosis most frequently present as sub acute or habitual meningitis, or as tuberculoma, which can beget spaceenwrapping lesions. CNS involvement can do alone or with pulmonary or circulated tuberculosis, the ultimate appertained to as Miliary tuberculosis. The vulnerable response to granuloma rupture leads to tuberculous exudates accumulation, which can beget vasculitis and infarctions in the cerebral arterial system, contributing to World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 116 neurological poverties. Cranial whim-whams impairment can affect from infarction or contraction. In a mouse model, increased TNFnascence product in the exudates was linked to the complaint’s progression. Hydrocephalus is more common and progressive in children than grown-ups with tuberculous meningitis. 4. Opinion 4.1. Treatment of TB complaint involves the following: • Signs and symptoms harmonious with TB • Casket-ray • Clinical judgment • Bacteriology, including • AFB smear microscopy • Nucleic Acid Modification Testing (NAAT) • Culture and identification • medicine vulnerability testing (DST) 5. Epidemiology ( 09) Despite a recent worldwide decline in incident cases, tuberculosis remains a leading cause of death encyclopedically. Onethird of the world’s population is infected with Mycobacterium tuberculosis, which progresses to active complaint in roughly 10 of individualities. In 2015, the World Health Organization estimated 10.4 million incident cases of tuberculosis worldwide, with 10 being in children and 11 in individualities living with mortal immunodeficiency contagion (HIV). Tuberculous meningitis accounts for 1 – 2 of active tuberculosis cases, and in regions with concurrent HIV and tuberculosis pandemics, M. tuberculosis has come a leading cause of bacterial meningitis, alongside pathogens like Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae. Unfortunately, about half of all tuberculous meningitis cases affect in severe disability or death. 6. Tb treatments (10-13) 6.1. TB treatment rules include • TB Infection (LTBI) treatment options • 9 months of Isoniazid • 4 months of Rifampin • 3 months of isoniazid plus Rifapentine • TB complaint (pulmonary, medicine-susceptible TB) • 6month standard authority • ferocious phase 2 months of Isoniazid, Rifampin, Ethambutol, and Pyrazinamide • Durability phase 4 months of Isoniazid and Rifampin. 7. Treatments 7.1. Medicine-Resistant Tuberculous Meningitis The global challenge of medicineresistant tuberculosis is aggravated by the specific pitfalls posed by tuberculous meningitis, which has advanced case-casualty rate than other forms of tuberculosis. Treatment for known or suspected medicine-resistant tuberculous meningitis can be supported by remedial medicine monitoring, given the variable pharmacokinetics and narrower remedial indicator of numerous alternate-line anti-tuberculosis medicines. 7.2. Isoniazid Resistance Isoniazid distributes freely into cerebrospinal fluid, both in the presence and absence of inflamed meninges, and demonstrates bactericidal exertion against M.tuberculosis. These pharmacokinetic and pharmacodynamic parcels punctuate its central part in treating tuberculous meningitis. Encyclopedically, Isoniazid nonresistance is the most current form of medicineresistant tuberculosis. Among 1614 tuberculous meningitis cases in the USA over a 12time World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 117 period, the odds of death before completing treatment were doubly as high among cases with Isoniazidresistant complaint. The association between original Isoniazid resistance and death was also significant among 186 HIVinfected tuberculous meningitis cases in Vietnam, with the fresh observation that redundant mortality due to Isoniazid resistance didn't appear until after the first 60 days of treatment. Interestingly, this time-dependent relationship between Isoniazid resistance and death was also observed among tuberculous meningitis cases in New York City, USA. Therefore, Isoniazidresistant tuberculous meningitis may offer an occasion to impact the course of the complaint by early intensification of remedy. While boosted remedy with highcure Rifampin and a fluoroquinolone didn't show an overall survival benefit among Vietnamese cases, there was a survival benefit among HIVuninfected tuberculous meningitis cases with Isoniazidresistant complaint. Importantly, the survival benefit of boosted treatment was topmost when the intensification passed at the launch of tuberculosis treatment, rather than in response to medicine vulnerability testing. Enforcing these findings in clinical practice would bear either a rapid-fire individual test for Isoniazid resistance in tuberculous meningitis cases or the use of threat factors for Isoniazid resistance, similar as tuberculosis contact history or the epidemiology of Isoniazidresistant complaint in the original population. 7.3. Multidrug Resistance Multidrugresistant tuberculous meningitis, defined as resistance to both Isoniazid and Rifampin with or without resistance to other agents, carries a poor prognostic. The pronounced increase in mortality of tuberculous meningitis when rifampin resistance is added to isoniazid resistance underscores the significance of rifampin in the treatment authority, despite its limited penetration into cerebrospinal fluid compared to isoniazid. Over a 12time period in the USA, 19 of 26(73) cases with multidrugresistant tuberculous meningitis failed before completing tuberculosis treatment. Among 16 cases with multidrugresistant tuberculous meningitis in the boosted remedy trial in Vietnam (including a single case with rifampinresistant, isoniazid-susceptible complaint), 11 failed before completing treatment, with a median time to death of 27 days from treatment inauguration. Successful treatment of multidrugresistant tuberculous meningitis is primarily reported in case studies, including the use of intrathecal administration of levofloxacin and amikacin. Linezolid may also be a useful alternateline medicine grounded on recent clinical tests in Chinese children and grown-ups. 7.4. LongTerm Neurologic issues Among Survivors Neurologic sequela performing from tuberculous meningitis includes hydrocephalus, stroke, cranial whim-whams paralysis, seizures, and mass lesions, with the threat of these complications adding with individual detainments. In a clinical trial of dexamethasone in Vietnam, 14 of actors had severe disability at 5 times of followup, with no difference between the dexamethasone and placebo arms. Among HIVuninfected tuberculous meningitis cases in New York City who successfully completed treatment, there was no fresh mortality compared to ageand coitusmatched controls over a 10time follow-up period, although differences in neurologic morbidities, which didn't impact survival, weren't measured. A cohort study of 806 US tuberculous meningitis cases using executive claims data linked rates of neurologic complications at 1-time following opinion stroke (15), seizures (12), and visual impairment (19). Almost of these complications passed during the original hospitalization. A methodical review of 19 pediatrics tuberculous meningitis studies, which included an aggregate of 1636 children treated for tuberculous meningitis, reported a 19-mortality rate, with 54 of survivors passing neurologic complications. Further exploration is demanded to completely understand the burden of tuberculous meningitis in highprevalence settings, especially the longterm consequences of endless disabilities among nonwage. 8. Types of tuberculosis Tuberculosis (TB) is a contagious complaint primarily caused by Mycobacterium tuberculosis. TB is classified into different types grounded on colorful factors similar as the point of infection, the form of the complaint, and the resistance to treatment. The primary orders of tuberculosis include pulmonary TB, extra pulmonary TB, medicineresistant TB, and idle TB. Each of these orders can be further divided into more specific types depending on the clinical and microbiological characteristics. 8.1. Pulmonary Tuberculosis (PTB) Pulmonary tuberculosis is the most common form of TB, and it primarily affects the lungs. The complaint is transmitted through airborne driblets when a person with active TB coughs or sneezes. Symptoms of pulmonary TB generally include patient cough, haemoptysis (coughing up blood), night sweats, weight loss, fever, and fatigue. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 118 • Cavitary TB In some cases of pulmonary TB, the infection leads to the conformation of depressions in the lungs due to towel destruction. This form is more severe and increases the threat of transmission to others. • Miliary TB This form occurs when the bacteria spread to other corridor of the body through the bloodstream. Its ca begets wide infection, affecting organs similar as the liver, spleen, and bone gist. 8.2. Extra pulmonary Tuberculosis (EPTB) Extra pulmonary TB occurs when the infection affects organs outside the lungs. Extra pulmonary TB is more common in individualities with weakened vulnerable systems, similar as those with HIV/ AIDS. • Lymphatic TB This is one of the most common forms of extra pulmonary TB. It generally involves the lymph bumps, which come enlarged and tender. It’s frequently seen in children and in immune compromised cases. • Bone and common TB Tuberculosis can infect bones and joints, causing osteoarticular TB. The chine (Pott’s complaint) is the most generally affected area. It leads to reverse pain, disfigurement, and, in severe cases, palsy. • Genitourinary TB This affects the feathers, bladder, and reproductive organs. Symptoms may include haematuria (blood in the urine), dysuria (painful urination), and pelvic pain. • TB of the CNS (Central Nervous System) Tuberculosis can affect the brain and meninges, leading to conditions similar as tuberculous meningitis, which can beget neurological poverties, confusion, and seizures. • Peritoneal TB Involves the peritoneum, the filling of the abdominal depression, causing abdominal pain, ascites, and peritonitis. 8.3. Idle Tuberculosis Idle tuberculosis infection (LTBI) occurs when a person has been infected with M. tuberculosis but doesn't show symptoms and isn't contagious. In idle TB, the bacteria remain dormant within the body and can come active if the vulnerable system weakens. People with idle TB are generally detected through a positive tuberculin skin test (TST) or interferongamma release assay (IGRA). Without treatment, idle TB can progress to active TB complaint. 8.4. MedicineResistant Tuberculosis (DR-TB) Medicineresistant tuberculosis is a form of TB that doesn't respond to the standard treatment authority, which generally includes a combination of antibiotics similar as isoniazid and rifampin. Medicine resistance arises due to mutations in the bacteria, and it’s frequently the result of indecorous treatment rules or non-compliance with remedy. • MultidrugResistant TB (MDRTB) this form of TB is resistant to at least isoniazid and Rifampin, the two most potent firstline anti-TB medicines. MDRTB requires longer treatment with alternateline medicines, which may be less effective and more precious. • Considerably medicineResistant TB (XDRTB) This is an indeed more resistant form of TB that's resistant to at least four of the core anti-TB medicines, including any fluoroquinolone and one of the alternatesline injectable medicines. XDRTB is delicate to treat and has a lower cure rate than MDRTB. • Completely medicineResistant TB (TDRTB) this is an extremely rare form of TB that shows resistance to all known anti-TB medicines, including both firstline and alternateline specifics. Treatment options for TDRTB are limited and frequently ineffective. 8.5. Primary Tuberculosis Primary tuberculosis occurs when a person is infected with M. tuberculosis for the first time. In almost cases, the body’s vulnerable system is suitable to control the infection and help it from progressing to active complaint. Still, in some individuality, the infection may develop into primary progressive tuberculosis, where the bacteria multiply and beget active complaint in the lungs or other organs. 8.6. Secondary Tuberculosis Secondary tuberculosis, also known as reactivation TB, occurs when latent TB becomes active, frequently due to a weakened vulnerable system. This can be times after the original infection, frequently touched off by conditions similar as HIV/ AIDS, malnutrition, or immunosuppressive treatments. Secondary TB is most frequently pulmonary, but it can also involve extra pulmonary spots. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 119 8.7. Circulated Tuberculosis Circulated tuberculosis refers to the wide spread of M. tuberculosis throughout the body, frequently involving multiple organs. This type of TB is generally seen in immune compromised individualities, particularly those with advanced HIV/ AIDS. Miliary TB is a form of circulated TB. 8.8. Tuberculosis in Children Tuberculosis in children frequently presents else than in grown-ups. Pediatrics TB is more likely to be extra pulmonary and is frequently diagnosed latterly due to the absence of classic symptoms like coughs and foam product. Lymph knot TB, abdominal TB, and TB meningitis are common forms in children. Also, children fewer than five times old are at lesser threat of developing severe forms of TB, similar as TB meningitis and circulated TB. 9. Drug classification :( 14-21) Tuberculosis (TB) treatment relies on a combination of drugs to ensure effectiveness and prevent the development of resistance. TB drugs are classified into different categories based on their mechanisms of action, and these include firstline, second-line, and other drugs used in special cases like drug-resistant TB. Understanding the mechanisms of these drugs helps to guide their appropriate use and enhance their efficacy in treating TB. 9.1. First-Line Drugs First-line drugs are the core drugs used in the treatment of tuberculosis. These drugs are highly effective against Mycobacterium tuberculosis and are typically used in combination for the initial treatment phase. They are considered the most potent drugs for treating TB and have the least risk of causing drug resistance when used properly. • Isoniazid (INH) o Mechanism of Action: Isoniazid is a bactericidal drug that inhibits the synthesis of mycolic acids, which are essential components of the bacterial cell wall in M. tuberculosis. This disruption leads to the weakening and eventual death of the bacteria. Isoniazid is especially effective during the rapid division phase of the bacteria. o Resistance: Resistance can develop due to mutations in the in-hA gene, which affects the target enzyme, or mutations in the katG gene, which codes for catalase-peroxidase, an enzyme involved in the activation of isoniazid. • Rifampin (RIF) o Mechanism of Action: Rifampin is a bactericidal drug that works by inhibiting bacterial RNA polymerase, thus preventing the transcription of bacterial DNA into RNA. This inhibition prevents the bacteria from synthesizing essential proteins, leading to bacterial death. Rifampin is highly effective in both active and latent TB. o Resistance: Resistance to Rifampin generally occurs through mutations in the probe gene, which encodes the RNA polymerase beta-subunit, the target of Rifampin. • Pyrazinamide (PZA) o Mechanism of Action: Pyrazinamide is bactericidal in acidic environments, such as those found within macrophages or in the intracellular environment. It is thought to inhibit the synthesis of mycolic acids, as well as disrupt the function of bacterial membrane transport proteins. The exact mechanism remains not fully understood. o Resistance: Resistance is typically caused by mutations in the pncA gene, which encodes the enzyme Pyrazinamide, responsible for converting Pyrazinamide into its active form. • Ethambutol (EMB) o Mechanism of Action: Ethambutol is bacteriostatic and inhibits the synthesis of the mycobacterium cell wall by blocking the enzyme arabinosyl transferase. This inhibition prevents the formation of arabinogalactan, a critical component of the mycobacterium cell wall, leading to bacterial cell death. o Resistance: Resistance occurs due to mutations in the embB gene, which encodes the arabinosyl transferase enzyme. • Streptomycin (SM) o Mechanism of Action: Streptomycin is an amino glycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit of M. tuberculosis, leading to misreading of the mRNA and the production of dysfunctional proteins, ultimately killing the bacteria. o Resistance: Resistance to streptomycin is primarily due to mutations in the rpsL and rrs genes, which encode components of the ribosomal subunit. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 120 9.2. Second-Line Drugs Second-line drugs are used when the first-line drugs are ineffective, either due to resistance or intolerance. These drugs are generally more toxic and less effective than first-line drugs, and their use should be carefully monitored. • Fluoroquinolone (e.g., Levofloxacin, Moxifloxacin, Gatifloxacin) o Mechanism of Action: Fluoroquinolone are bactericidal and inhibit DNA gyrase and topoisomerase IV, enzymes responsible for unwinding DNA during replication. By inhibiting these enzymes, fluoroquinolone prevent DNA replication and repair, leading to bacterial death. o Resistance: Resistance to fluoroquinolone occurs through mutations in the gyrA and parC genes, which affect the target enzymes. • Kanamycin and Amikacin o Mechanism of Action: Both kanamycin and amikacin are amino glycosides, similar to streptomycin. They inhibit protein synthesis by binding to the 30S ribosomal subunit, leading to misreading of mRNA and the production of defective proteins. o Resistance: Resistance to these drugs is typically due to enzymatic modification of the drug, mediated by amino glycoside-modifying enzymes. • Capreomycin o Mechanism of Action: Capreomycin is another amino glycoside that inhibits protein synthesis by binding to the 70S ribosomal subunit. It interferes with the formation of the ribosomal complex, thereby inhibiting protein translation. o Resistance: Resistance to capreomycin occurs through mutations in the rpsL gene or through the acquisition of resistance genes that modify the drug. • Clofazimine o Mechanism of Action: Clofazimine is a riminophenazine derivative that binds to DNA and interferes with bacterial DNA replication and protein synthesis. It also exhibits anti-inflammatory properties, which may help in the treatment of drug-resistant TB. o Resistance: Resistance to clofazimine is rare but can occur due to mutations in the mycobacterium DNA repair mechanisms. • Ethionamide o Mechanism of Action: Ethionamide is similar to isoniazid in its mechanism of action, as it inhibits the synthesis of mycolic acids in the mycobacterium cell wall. o Resistance: Resistance to ethionamide is generally caused by mutations in the inhA gene or other genes related to cell wall synthesis. • Cycloserine o Mechanism of Action: Cycloserine inhibits the synthesis of the bacterial cell wall by interfering with the formation of peptidoglycan cross-links. It is bacteriostatic and is used as a second-line agent in the treatment of multidrug-resistant TB. o Resistance: Resistance to cycloserine arises through mutations in the alr and d-cycloserine genes involved in cell wall synthesis. 9.3. Other Medicines in Special Cases These medicines are generally used in the treatment of resistant TB or in cases with specific requirements, similar as those with expensive medicine resistance or co-infection with HIV. • Bedaquiline Medium of Action Bedaquiline is a new medicine that inhibits the ATP synthase enzyme in M. tuberculosis, dismembering the bacteria's energy product. This leads to the eventual death of the bacteria. • Resistance: Resistance to bedaquiline is primarily caused by mutations in the atpE gene, which encodes the target enzyme. • Delamanid Medium of Action Delamanid is a nitroimidazole that inhibits the conflation of mycolic acids in the bacterial cell wall by inhibiting the enzyme InhA. It also affects the bacterial respiratory chain, dismembering energy product. • Resistance: It is caused by mutations in the in A gene and other targets involved in cell wall biosynthesis. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 121 9.4. Mechanisms of Drug Resistance in TB Drug resistance in TB arises through mutations in specific genes within M. tuberculosis. These mutations can confer resistance to one or further medicines, making treatment more delicate. Some of the most common mechanisms of resistance include. Target Enzyme Mutations numerous TB medicines work by inhibiting specific enzymes(e.g., RNA polymerase for rifampin, mycolic acid conflation for isoniazid). Mutations in the genes garbling these enzymes can reduce the medicine's effectiveness. Efflux Pumps M. tuberculosis can have efflux pumps that laboriously transport medicines out of the bacterial cell, reducing the medicine's intracellular attention. Some resistance mechanisms involve the revision of the medicine itself through enzymatic action similar as the acetylating of isoniazid or the revision of amino glycosides like kanamycin. 10. Operation of Tuberculosis (TB) The operation of tuberculosis (TB) involves a combination of pharmacological treatment, applicable individual procedures, and addressing public health strategies to control its spread. The foundation of TB treatment is antimicrobial remedy, which requires the use of multiple medicines to help the development of medicine-resistant strains. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) give detailed guidelines for the treatment of both medicine-susceptible and medicineresistant TB. 10.1. FirstLine medicine Treatment for medicine-Susceptible The treatment of medicine-susceptible TB generally involves a sixmonth authority of four first-line medicines. These medicines • Isoniazid (INH) An antibiotic that inhibits the conflation of mycolic acids in the bacterial cell wall. • Rifampin (RIF) A broaddiapason antibiotic that interferes with bacterial RNA conflation by binding to bacterial RNA polymerase. • Pyrazinamide (PZA) A pro drug that's converted into its active form inside the acidic terrain of the phagosome, targeting the bacteria during the intracellular phase. • Ethambutol (EMB) A medicine that inhibits the conflation of the bacterial cell wall by snooping with arabinogalactan conflation. This authority is recommended for cases with recently diagnosed, medicine-susceptible TB. The first two months of treatment, known as the ferocious phase, correspond of all four medicines, while the remaining four months, known as the durability phase, involve a combination of isoniazid and rifampin. 10.2. MedicineResistant TB The treatment of multidrugresistant TB (MDRTB), which is resistant to at least isoniazid and rifampin, and considerably medicineresistant TB (XDRTB), which is also resistant to fluoroquinolone and alternateline injectable medicines, is more complicated. MDRTB and XDRTB bear the use of alternateline medicines, which may include • Fluoroquinolone (e.g., levofloxacin, moxifloxacin) • Injectable agents (e.g., amikacin, kanamycin, capreomycin) • Bedaquiline A newer medicine that inhibits the ATP synthase of the mycobacterium, making it effective against resistant strains. • Delamanid Another newer medicine that inhibits mycobacterium cell wall conflation. Treatment rules for MDRTB or XDRTB are more prolonged, frequently lasting 1824 months, and have an advanced threat of adverse goods. Also, the success rate for these treatments is lower than that of medicine-susceptible TB. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 122 10.3. Adherence to Treatment Adherence to the TB treatment authority is pivotal for precluding the development of medicine resistance and icing effective treatment. Directly observed remedy (DOT) is a strategy used to cover adherence, where healthcare providers observe cases taking their specifics to ensure the full course of treatment is completed. DOT has been shown to ameliorate adherence and cure rates in TB treatment. 10.4. Operation of idle TB Infection (LTBI) Idle TB infection occurs when the vulnerable system contains the Mycobacterium tuberculosis bacteria but doesn't allow them to multiply, therefore precluding the development of active TB complaint. LTBI can be treated with preventative remedy to reduce the threat of progression to active complaint. The most generally used treatments for LTBI include • Isoniazid monotherapy for 69 months • Rifampin monotherapy for 4 months • Isoniazid and Rifapentine formerly daily for 3 months (the 3HP authority) These curatives are recommended for individualities at high threat of developing TB, similar as those with HIV, close connections of TB cases, and people with compromised vulnerable systems. 10.5. Probative Care and Management of Side goods TB treatment can affect in adverse goods due to the dragged use of multiple medicines. Common side goods include hepatotoxicity, gastrointestinal disturbances, and supplemental neuropathy, especially from isoniazid. probative care, including characteristic treatment and monitoring for medicinerelated venom, is an essential part of TB operation. In some cases, cases may need to discontinue or switch specifics if adverse responses do. 10.6. Surgical Intervention Surgical intervention in TB is reserved for cases where medical treatment is inadequate or complications arise. Surgery may be necessary in the case of expansive lung damage, pleural TB, or medicineresistant TB where drug alone cannot achieve a cure. Surgical options may include resection of diseased lung towel or pleurectomy for cases with complicated TB. 10.7. Public Health and Infection Control Public health measures are also critical to TB operation, particularly in highfrequency settings. This includes insulation of cases with active TB, especially those with medicineresistant TB, until they're no longer contagious. Contact dogging and webbing of individualities who may have been exposed to a person with TB is essential for precluding farther transmission (WHO, 2020). In healthcare settings, infection control measures similar as proper ventilation and particular defensive outfit (PPE) for healthcare workers are necessary to help the spread of TB. 10.8. New Developments and Research Recent exploration has concentrated on perfecting the opinion, treatment, and forestallment of TB. New individual tools, including rapid-fire molecular tests similar as Gene pert, allow for faster discovery of TB and medicine resistance (Boehme et al., 2010). New medicine campaigners, similar as bedaquiline and delamanid, offer stopgap for cases with medicine-resistant TB. Also, there's ongoing exploration into the development of a TB vaccine to give a more effective preventative measure. 11. Sign and symptoms of tuberculosis (TB) (22-30) Tuberculosis (TB) is a serious contagious complaint primarily caused by Mycobacterium tuberculosis. TB affects the lungs in the maturity of cases, but it can also affect other corridor of the body, leading to extra pulmonary TB. The signs and symptoms of TB vary depending on whether the complaint is pulmonary or extra pulmonary, and whether it's active or idle. This section will bandy the common signs and symptoms of TB, pressing the differences between active and idle forms, as well as pulmonary and extra pulmonary instantiations. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 129 Table 4 Medicinal plants and natural products showing in vitro anti-TB activity (32) S.N o Plant species Plant family Plan t used Extract Compound class Active constituents 01. Abrusprecatorius Fabaceae Aeria l parts Dichloro Methane fraction Isoflavanquinoe Abruquinone,Methy l gallate 02. Acaciafarnesiana Mimosaceae Fruit Methanolic extract Parabens, flavanones (2S)-Naringenin 7O-βgalloylglucopyranos ide (3) showed activity against multidrug resistant M. tuberculosis G122 with MIC of 50 μg/ml by MABA 03. Aglaiaforbesii Meliaceae Leaf Dichloromethanefr action Benzopyranflavagli nes Desacetylpyramidag lain D against M. tuberculosis Ra with MIC of 25 μg/ml by MABA 04. Allanblackia floribunda Guttiferae Root bark Successivelymacer atedin dichloromethane methanol (1:1) and methanol for4h Biflavonoids Morelloflavonewith the MIC of 19.53 and 39.06 μg/ ml against M. smegmatis and M. tuberculosis, respectively, by MABA 05. Allium neapolitanum Alliaceae Bulb Chloroformextract Canthinone Canthin-6-one, 8hydroxy-canthin-6one 06. Alliumsativum Liliaceae Bulb Petroleumetherext ract Fattyacids Lauric acid and myristic acid 07. Allophylusedulis Sapindaceae Leaf Hydrodistillation Cycloprop[e]azule n-4-ol Viridiflorol 08. Alnusincana Betulaceae Bark Methanolextract Triterpenes Betulin, betulinic acid, betulone 09. Alpinia katsumadi Zingiberacea e Seed n-Hexane Diarylheptanoids Trans, trans-1,7diphenylhepta-4,6dien-3-one 10. Amphipterygium astringens Anacardiacea e Stem, bark Dichloromethane/ methanol (1:1) Tirucallanes (14β, 24E)-3oxolanosta-7,24dien-26-oic acid (16) and (14β,24E)- 3-hydroxylanosta7,24-dien-26-oic acid World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 130 Table 5 Important anti-TB traditional medicinal plants in literature by the systemic survey on the prescribed formula (32) S. No Species number Family number Main families Country/region 01. 90 44 Fabaceae (13), Asteraceae (7), Moraceae (5), Rutaceae (4) Districts of Mpigi and Butambala, Uganda 02. 35 22 Fabaceae (5), Rutaceae (4), Apocynaceae (3), Menispermaceae (3), Madhya Pradesh, India 03. 132 45 Annonaceae (14), Zingiberaceae (12), Rutaceae (10), Annonaceae(10), Asteraceae(8), Euphorbiaceae(8), Fabaceae(7) Southeast Asian 04. 10 8 Fabaceae (3), Cannellaceae(1), Rubiaceae(1), Anacardiaceae(1), Rutaceae(1), Mirtaceae(1), Merlucciidae(1), Guttiferae(1) Lake Victoria Basin (Uganda, Kenya and Tanzania) 05. 14 8 Euphorbiaceae (4), Verbenaceae (3), Rutaceae (2) Lake Victoria region and the Samburu community 06. 2 2 Achillea millefolium (1), Dryopteris Stewartii (1) Kell village, Neelum valley, Azad Kashmir, Pakistan 07. 4 3 Amaryllidaceae (1), Lauraceae (1), Amaranthaceae (1), Asteraceae (01) Sulaymaniyah province, Kurdistan, Iraq, 08. 22 18 Liliaceae (3), Euphorbiaceae(2), Verbenaceae(2), India 09. 6 6 Vitaceae (1), Poaceae(1), Pinaceae(1), Musaceae(1), Rosaceae(1), Leguminosae(1) Arabian Peninsula 10. 2 2 Asteraceae (1) Dryopteridaceae(1) Pakistan 11. 70 44 Arecaceae (4), Euphorbiaceae (4), Fabaceae (3), Piperaceae (3), Malaysia 12. Conclusion Tuberculosis (TB) remains a critical global health issue, worsened by drug resistance and complex disease presentations. Although synthetic drugs are effective, their side effects have driven interest in safer, plant-based alternatives. Medicinal plants offer a cost-effective and widely accessible source of potential treatments, yet many remain underexplored for clinical application. The rich diversity of bioactive compounds in these plants presents an opportunity for innovative therapies. Integrating traditional knowledge with modern medicine could provide safer and more effective solutions. Advancing research in this field is vital for overcoming TB’s challenges and improving global health outcomes. Compliance with ethical standards Acknowledgments The authors are very cordially grateful to my parents and my esteemed respected guide Dr. K. Praveena, H. Hariharan, Smt. Gandhimathi college of Pharmacy, Tiruvannamalai, For his supervision advice and guidance for providing encouragement and facilities for compiling this work. Disclosure of conflict of interest The author(s) declare that they have no competing interests. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 131 References [1] World Health Organization (WHO). (2020). Global tuberculosis report 2020. Retrieved from https://www.who.int/tb/publications/global_report [2] CDC TB website: www.cdc.gov/tb/ [3] State & Local TB Control Offices: https://www.cdc.gov/tb/php/tb programs/index.html [4] Find TB Resources: https://findtbresources.cdc.gov [5] TB Centers of Excellence: https://www.cdc.gov/tb-programs/php/about/tb-coe.html [6] Face book: www.facebook.com/CDCTB [7] X (formerly Twitter): www.twitter.com/cdc tb. [8] Akosua Adom Agyeman, Richard Ofori-Asenso, (2017), Tuberculosis—an overview, Journal of Public Health and Emergency; 1:7. [9] Zignol, M., et al. (2016). The Epidemiology of Drug-Resistant Tuberculosis. The Lancet Infectious Diseases, 16(3), 1–5. [10] Centers for Disease Control and Prevention (CDC). (2021). Tuberculosis (TB). Retrieved from https://www.cdc.gov/tb [11] Comas, I., Coscolla, M., Luo, T., et al. (2013). Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans. Nature Genetics, 45(10), 1183-1189. https://doi.org/10.1038/ng.2744 [12] Fischer, M., Beier, J., & Silva, D. (2019). Mycobacterium bovis: A neglected zoonotic pathogen in a globalized world. Frontiers in Veterinary Science, 6, 350. https://doi.org/10.3389/fvets.2019.00350 [13] Raviglione, M. C., & Sulis, G. (2016). Tuberculosis 2015: Burden, challenges and strategy for control and elimination. Infectious Disease Reports, 8(2), 19-22. https://doi.org/10.4081/idr.2016.6078World Health Organization (WHO). (2023). Tuberculosis Fact Sheet. Retrieved from https://www.who.int/news-room/factsheets/detail/tuberculosis [14] Tiberi, S., et al. (2020). Tuberculosis: The Role of Extrapulmonary Manifestations. European Respiratory Journal, 56(1), 1900803. [15] Dorman, S. E., et al. (2016). New and Emerging Drugs for Tuberculosis. The Lancet Infectious Diseases, 16(3), 1– 5. [16] Diacon, A. H., et al. (2020). Mechanisms of Resistance and Treatment of Drug-Resistant Tuberculosis. Clinical Microbiology and Infection, 26(6), 805–815. [17] Boehme, C. C., Nabeta, P., Hillemann, D., et al. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine, 363(11), 1005-1015. https://doi.org/10.1056/NEJMoa0907847 [18] Jin, C., Zhou, J., & Lu, W. (2016). Surgical treatment for drug-resistant tuberculosis. The Lancet Respiratory Medicine, 4(11), 808-815. https://doi.org/10.1016/S2213-2600(16)30153-9 [19] Lönnroth, K., Migliori, G. B., & D'Ambrosio, L. (2014). The importance of adherence to tuberculosis treatment: A global perspective. International Journal of Tuberculosis and Lung Disease, 18(7), 755-760. https://doi.org/10.5588/ijtld.14.0221 [20] Raviglione, M. C., & Sulis, G. (2016). Tuberculosis 2015: Burden, challenges and strategy for control and elimination. Infectious Disease Reports, 8(2), 19-22. https://doi.org/10.4081/idr.2016.6078 [21] Tameris, M. D., Hatherill, M., & Landry, B. S. (2013). Safety and efficacy of the MVA85A tuberculosis vaccine in infants. New England Journal of Medicine, 369(19), 1707-1717. https://doi.org/10.1056/NEJMoa1303653. [22] Zumla, A., George, A., Sharma, V., et al. (2014). The global burden of tuberculosis: Results of the Global Tuberculosis Control 2014 survey. The Lancet, 379(9836), 2045-2055. https://doi.org/10.1016/S01406736(14)60993-6. [23] Dheda, K., et al. (2017). Tuberculosis: Symptoms, Diagnosis, and Treatment. The Lancet, 389(10082), 297–309. [24] Horsburgh CR Jr, Barry CE 3rd, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373(22):2149-2160. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 114–132 132 [25] Esposito S, Bosis S, Morlacchi L, et al. Levofloxacin for the treatment of Mycobacterium tuberculosis infections in children. J Chemother. 2013;25(2):61-70. [26] Lange C, Chesov D, Dooley KE, et al. new drugs and treatment regimens for tuberculosis. Lancet Respir Med. 2019;7(3):258-259. [27] Gupta S, Arya V, et al. Ayurvedic Plants with Anti-Tubercular Properties. Int J PharmTechRes.2011;3(2):875-876. [28] Mukherjee PK, et al. Traditional Medicine in the Treatment of Tuberculosis. J Ethnopharmacol.2010;130(1):1-13. [29] World Health Organization. The Use of Herbal Medicines in TB Management. WHO Monograph Series; 2020. Singh R, et al. Therapeutic Potential of Medicinal Plants in Tuberculosis Management. J Ayurveda Integr Med. 2015;6(1):3-10. [30] Kaur S, et al. Antimicrobial Properties of Indian Medicinal Plants. Pharm Biol. 2018;56(1):91-103. Vikrant Arya, A Review on Anti-Tubercular Plants, international journal of Pharma Tech Research (2011), volume 3, NO. 2, pp 872-880, ISSN : 0974-4304. [31] Vikrant Arya, A Review on Anti-Tubercular Plants, international journal of Pharma Tech Research (2011), volume 3, NO. 2, pp 872-880, ISSN: 0974-4304. [32] Yuhui xu, et al. Traditional medicinal plants as a source of Anti-TB drugs: A system review, Hindawi bioMed Research International, volume 2021, article ID 9910365, 36 pages